Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
Autor: | Pascale Tomasini, Julie Egea, M. Souquet-Bressand, Fabrice Barlesi, Laurent Greillier |
---|---|
Přispěvatelé: | Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Assistance Publique - Hôpitaux de Marseille (APHM), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS) |
Rok vydání: | 2019 |
Předmět: |
Alectinib
Lung Neoplasms [SDV]Life Sciences [q-bio] Review 0302 clinical medicine Piperidines hemic and lymphatic diseases Carcinoma Non-Small-Cell Lung brain metastases Anaplastic lymphoma kinase MESH: Protein Kinase Inhibitors Pharmacology (medical) Anaplastic Lymphoma Kinase MESH: Anaplastic Lymphoma Kinase Gene Rearrangement 0303 health sciences Brain Neoplasms MESH: Drug Resistance Neoplasm 3. Good health MESH: Piperidines 030220 oncology & carcinogenesis MESH: Brain Neoplasms Treatment strategy Non small cell Pulmonary and Respiratory Medicine MESH: Mutation MESH: Gene Rearrangement Carbazoles [SDV.BC]Life Sciences [q-bio]/Cellular Biology 03 medical and health sciences medicine Humans alectinib Lung cancer Protein Kinase Inhibitors non-small cell lung cancer 030304 developmental biology lcsh:RC705-779 MESH: Humans business.industry ALK-Positive lcsh:Diseases of the respiratory system medicine.disease MESH: Lung Neoplasms Clinical trial ALK Drug Resistance Neoplasm Mutation Cancer research business MESH: Carbazoles MESH: Carcinoma Non-Small-Cell Lung |
Zdroj: | Therapeutic Advances in Respiratory Disease Therapeutic Advances in Respiratory Disease, SAGE Publishing, 2019, 13, pp.175346661983190. ⟨10.1177/1753466619831906⟩ Therapeutic Advances in Respiratory Disease, Vol 13 (2019) Therapeutic Advances in Respiratory Disease, 2019, 13, pp.175346661983190. ⟨10.1177/1753466619831906⟩ |
ISSN: | 1753-4666 1753-4658 |
DOI: | 10.1177/1753466619831906⟩ |
Popis: | International audience; Molecular profiling of metastatic nonsquamous non-small cell lung cancer (NSCLC) is required to guide the treatment strategy. Anaplastic lymphoma kinase ( ALK) gene rearrangements are found in approximately 5% of lung adenocarcinomas and are associated with specific clinical features including a high risk of brain metastases. Crizotinib was the first ALK inhibitor developed and it demonstrated improved outcomes in patients with ALK-positive advanced NSCLC in comparison with chemotherapy. However, despite an initial response, all ALK-positive NSCLC patients develop acquired resistance to crizotinib. Because the most frequent mechanism of resistance is the development of a secondary ALK mutation, second (ceritinib, alectinib, brigatinib) and third-generation (lorlatinib) ALK inhibitors were developed. Alectinib is a second-generation ALK inhibitor and was shown to be effective for a broad spectrum of ALK rearrangements and ALK mutations. It was also shown to have high intracranial efficacy. In this article, we review clinical trial evidence of alectinib efficacy as well as publications reporting the experience of alectinib in daily practice, with a focus on brain metastases. |
Databáze: | OpenAIRE |
Externí odkaz: |